Deep Brain Nuclei T1 Shortening after Gadobenate Dimeglumine in Children: Influence of Radiation and Chemotherapy

References

1. 1.↵
   2. Errante Y,
   3. Cirimele V,
   4. Mallio CA, et al

   . Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014;49:685–90 doi:10.1097/RLI.0000000000000072 pmid:24872007

   CrossRefPubMed
2. 2.↵
   2. Quattrocchi CC,
   3. Mallio CA,
   4. Errante Y, et al

   . Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015;50:470–72 doi:10.1097/RLI.0000000000000154 pmid:25756685

   CrossRefPubMed
3. 3.↵
   2. McDonald RJ,
   3. McDonald JS,
   4. Kallmes DF, et al

   . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

   CrossRefPubMed
4. 4.↵
   2. Ramalho J,
   3. Castillo M,
   4. AlObaidy M, et al

   . High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 2015;276:836–44 doi:10.1148/radiol.2015150872 pmid:26079490

   CrossRefPubMed
5. 5.↵
   2. Weberling LD,
   3. Kieslich PJ,
   4. Kickingereder P, et al

   . Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol 2015;50:743–48 doi:10.1097/RLI.0000000000000206 pmid:26352749

   CrossRefPubMed
6. 6.↵
   2. Adin ME,
   3. Kleinberg L,
   4. Vaidya D, et al

   . Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol 2015;36:1859–65 doi:10.3174/ajnr.A4378 pmid:26294649

   Abstract/FREE Full Text
7. 7.↵
   2. Radbruch A,
   3. Weberling LD,
   4. Kieslich PJ, et al

   . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275:783–91 doi:10.1148/radiol.2015150337 pmid:25848905

   CrossRefPubMed
8. 8.↵
   2. Cao Y,
   3. Huang DQ,
   4. Shih G, et al

   . Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol 2015;206:414–19 doi:10.2214/AJR.15.15327 pmid:26700156

   CrossRefPubMed
9. 9.↵
   2. Zhang Y,
   3. Cao Y,
   4. Shih GL, et al

   . Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology 2017;282:516–25 doi:10.1148/radiol.2016152864 pmid:27513848

   CrossRefPubMed
10. 10.↵
    2. Schlemm L,
    3. Chien C,
    4. Bellmann-Strobl J, et al

    . Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients. Mult Scler 2017;23:963–72 doi:10.1177/1352458516670738 pmid:27679460

    CrossRefPubMed
11. 11.↵
    2. Eisele P,
    3. Alonso A,
    4. Szabo K, et al

    . Lack of increased signal intensity in the dentate nucleus after repeated administration of a macrocyclic contrast agent in multiple sclerosis: an observational study. Medicine 2016;95:e4624 doi:10.1097/MD.0000000000004624 pmid:27684794

    CrossRefPubMed
12. 12.↵
    2. Radbruch A,
    3. Weberling LD,
    4. Kieslich PJ, et al

    . High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol 2015;50:805–10 doi:10.1097/RLI.0000000000000227 pmid:26523910

    CrossRefPubMed
13. 13.↵
    2. Stojanov D,
    3. Aracki-Trenkic A,
    4. Vojinovic S, et al

    . Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2016;26:807–15 doi:10.1007/s00330-015-3879-9 pmid:26105022

    CrossRefPubMed
14. 14.↵
    2. Kanda T,
    3. Fukusato T,
    4. Matsuda M, et al

    . Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276:228–32 doi:10.1148/radiol.2015142690 pmid:25942417

    CrossRefPubMed
15. 15.↵
    2. Murata N,
    3. Gonzalez-Cuyar LF,
    4. Murata K, et al

    . Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 2016;51:447–53 doi:10.1097/RLI.0000000000000252 pmid:26863577

    CrossRefPubMed
16. 16.↵
    2. Robert P,
    3. Lehericy S,
    4. Grand S, et al

    . T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol 2015;50:473–80 doi:10.1097/RLI.0000000000000181 pmid:26107651

    CrossRefPubMed
17. 17.↵
    2. Frenzel T,
    3. Apte C,
    4. Jost G, et al

    . Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. Invest Radiol 2017;52:396–404 doi:10.1097/RLI.0000000000000352 pmid:28125438

    CrossRefPubMed
18. 18.↵
    2. Jost G,
    3. Lenhard DC,
    4. Sieber MA, et al

    . Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Invest Radiol 2016;51:83–89 doi:10.1097/RLI.0000000000000242 pmid:26606548

    CrossRefPubMed
19. 19.↵
    2. Hu HH,
    3. Pokorney A,
    4. Towbin RB, et al

    . Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams. Pediatr Radiol 2016;46:1590–98 doi:10.1007/s00247-016-3646-3 pmid:27282825

    CrossRefPubMed
20. 20.↵
    2. Flood TF,
    3. Stence NV,
    4. Maloney JA, et al

    . Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. Radiology 2017;282:222–28 doi:10.1148/radiol.2016160356 pmid:27467467

    CrossRefPubMed
21. 21.↵
    2. Roberts DR,
    3. Chatterjee AR,
    4. Yazdani M, et al

    . Pediatric patients demonstrate progressive T1-weighted hyperintensity in the dentate nucleus following multiple doses of gadolinium-based contrast agent. AJNR Am J Neuroradiol 2016;37:2340–47 doi:10.3174/ajnr.A4891 pmid:27469211

    Abstract/FREE Full Text
22. 22.↵
    2. Roberts DR,
    3. Holden KR

    . Progressive increase of T1 signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in the pediatric brain exposed to multiple doses of gadolinium contrast. Brain Dev 2016;38:331–36 doi:10.1016/j.braindev.2015.08.009 pmid:26345358

    CrossRefPubMed
23. 23.↵
    2. Miller JH,
    3. Hu HH,
    4. Pokorney A, et al

    . MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations. Pediatrics 2015;136:e1637–40 doi:10.1542/peds.2015-2222 pmid:26574593

    Abstract/FREE Full Text
24. 24.↵
    2. Kasahara S,
    3. Miki Y,
    4. Kanagaki M, et al

    . Hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with a history of brain irradiation. Radiology 2011;258:222–28 doi:10.1148/radiol.10100508 pmid:21045180

    CrossRefPubMed
25. 25.↵
    2. Radbruch A,
    3. Haase R,
    4. Kickingereder P, et al

    . Pediatric brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a macrocyclic gadolinium-based contrast agent. Radiology 2017;283:828–36 doi:10.1148/radiol.2017162980 pmid:28273007

    CrossRefPubMed
26. 26.↵
    2. Kanda T,
    3. Ishii K,
    4. Kawaguchi H, et al

    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

    CrossRefPubMed
27. 27.↵
    2. Kanda T,
    3. Osawa M,
    4. Oba H, et al

    . High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275:803–09 doi:10.1148/radiol.14140364 pmid:25633504

    CrossRefPubMed
28. 28.↵
    2. Montagne A,
    3. Barnes SR,
    4. Sweeney MD, et al

    . Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015;85:296–302 doi:10.1016/j.neuron.2014.12.032 pmid:25611508

    CrossRefPubMed
29. 29.↵
    2. Corot C,
    3. Petry KG,
    4. Trivedi R, et al

    . Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol 2004;39:619–25 doi:10.1097/01.rli.0000135980.08491.33 pmid:15377941

    CrossRefPubMed
30. 30.↵
    2. Doyle KP,
    3. Quach LN,
    4. Arceuil HE, et al

    . Ferumoxytol administration does not alter infarct volume or the inflammatory response to stroke in mice. Neurosci Lett 2015;584:236–40 doi:10.1016/j.neulet.2014.10.041 pmid:25449870

    CrossRefPubMed
31. 31.↵
    2. Kanal E,
    3. Maravilla K,
    4. Rowley HA

    . Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. AJNR Am J Neuroradiol 2014;35:2215–26 doi:10.3174/ajnr.A3917 pmid:24852287

    Abstract/FREE Full Text
32. 32.↵
    2. Bruce R,
    3. Wentland AL,
    4. Haemel AK, et al

    . Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide. Invest Radiol 2016;51:701–05 doi:10.1097/RLI.0000000000000259 pmid:26885631

    CrossRefPubMed
33. 33.↵
    2. Kanda T,
    3. Oba H,
    4. Toyoda K, et al

    . Recent advances in understanding gadolinium retention in the brain. AJNR Am J Neuroradiol 2016;37:E1–2 doi:10.3174/ajnr.A4586 pmid:26494697

    FREE Full Text